Delivery of Growth Factors to Enhance Bone Repair

The management of critical-sized bone defects caused by nonunion, trauma, infection, malignancy, pseudoarthrosis, and osteolysis poses complex reconstruction challenges for orthopedic surgeons. Current treatment modalities, including autograft, allograft, and distraction osteogenesis, are insufficie...

Full description

Saved in:
Bibliographic Details
Published in:Bioengineering (Basel) 2023-10, Vol.10 (11), p.1252
Main Authors: Ball, Jacob R, Shelby, Tara, Hernandez, Fergui, Mayfield, Cory K, Lieberman, Jay R
Format: Article
Language:English
Subjects:
Allografts
Autografts
Bioengineering
BMP
Bone grafts
Bone growth
Bone healing
Bone loss
Clinical trials
Collagen
Controlled release
critical-sized defect
Distraction osteogenesis
FDA approval
Fractures
Gene therapy
growth factor
Growth factors
Intracellular signalling
Kinases
Malignancy
Nonunion
Orthopedics
Osteolysis
Polymers
Proteins
stem cell
Tissue engineering
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The management of critical-sized bone defects caused by nonunion, trauma, infection, malignancy, pseudoarthrosis, and osteolysis poses complex reconstruction challenges for orthopedic surgeons. Current treatment modalities, including autograft, allograft, and distraction osteogenesis, are insufficient for the diverse range of pathology encountered in clinical practice, with significant complications associated with each. Therefore, there is significant interest in the development of delivery vehicles for growth factors to aid in bone repair in these settings. This article reviews innovative strategies for the management of critical-sized bone loss, including novel scaffolds designed for controlled release of rhBMP, bioengineered extracellular vesicles for delivery of intracellular signaling molecules, and advances in regional gene therapy for sustained signaling strategies. Improvement in the delivery of growth factors to areas of significant bone loss has the potential to revolutionize current treatment for this complex clinical challenge.
ISSN:2306-5354
2306-5354
DOI:10.3390/bioengineering10111252